OABIW
OmniAb Inc.NASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
1.17
52W High
$0.30
52W Low
$0.08
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
-187.60%
Forward P/E
—
PEG Ratio
—
About OmniAb Inc.
OmniAb Inc. is an innovative biotechnology company focused on the discovery and development of fully human therapeutic antibodies through its proprietary OmniAb platform, which offers a diverse array of antibody libraries. The company strategically targets therapeutic areas such as oncology and autoimmune disorders, positioning itself at the forefront of a rapidly evolving market. With a robust pipeline of products and key collaborations, OmniAb is well-equipped to capitalize on the increasing demand for cutting-edge antibody therapies, contributing significantly to advancements in personalized medicine and improved patient care.
Fundamentals
| Revenue (TTM) | $28.94M |
| Gross Profit (TTM) | $28.62M |
| EBITDA | $-33.44M |
| Operating Margin | -54.30% |
| Return on Equity | -20.30% |
| Return on Assets | -11.30% |
| Revenue/Share (TTM) | $0.24 |
| Book Value | $1.81 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 247.30% |
| Shares Outstanding | 0 |
| Float | $113.85M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
—
HV 20-Day
—
HV 30-Day
—
HV 60-Day
—
HV Rank
—
Data last updated: 7/9/2026